Policy Notices

• Clarification and Guidance for Applicants Preparing Applications for the Spring 2022 Due Dates During the COVID-19 Pandemic
  (NOT-OD-22-046)
  Office of the Director, NIH
  

• Extending the Special Exception to the NIH/AHRQ/NIOSH Post-Submission Material Policy During the COVID-19 Pandemic: August/October 2022 Councils
  (NOT-OD-22-047)
  Office of the Director, NIH
  

General Notices

• Notice of NIBIB Withdrawal from PAR-20-155, "Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (R01 Clinical Trial Optional)"
  (NOT-EB-21-031)
  National Institute of Biomedical Imaging and Bioengineering
  

• Notice of NIBIB Withdrawal from PAR-21-166, "Academic-Industrial Partnerships of Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Not Allowed)"
  (NOT-EB-21-032)
  National Institute of Biomedical Imaging and Bioengineering
  

• Notice of Information: Multi-Institute Interest in Pain Research
  (NOT-NS-22-057)
  National Institute of Neurological Disorders and Stroke
  National Center for Complementary and Integrative Health
  National Institute on Aging
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  National Institute on Drug Abuse
  National Institute of Dental and Craniofacial Research
  National Institute of Diabetes and Digestive and Kidney Diseases
  

• Maintaining Security and Confidentiality in NIH Peer Review: Rules, Responsibilities and Possible Consequences
  (NOT-OD-22-044)
  Office of the Director, NIH
  

• Notice of Pre-Application Webinar and FAQs for RFA-OD-22-002 Center for Rapid Surveillance of Tobacco (CRST) to Assess Changes in Use Behaviors, Product Marketing, and the Marketplace (U01 Clinical Trial Not Allowed)
  (NOT-OD-22-052)
  Office of Disease Prevention
  

• Request for Information (RFI): Inviting Comments and Suggestions on Updating the Strategic Plan for Trans-NIH Research to Cure Hepatitis B
  (NOT-AI-22-018)
  National Institute of Allergy and Infectious Diseases
  National Cancer Institute
  National Institute on Alcohol Abuse and Alcoholism
  National Institute of Diabetes and Digestive and Kidney Diseases
  National Institute on Minority Health and Health Disparities
  

• Request for Information (RFI): Research Challenges and Needs in the Interaction of Sleep and Emotion Regulation to Improve Health and Well-being across Health Conditions
  (NOT-OD-22-053)
  Office of Behavioral and Social Sciences Research
  National Cancer Institute
  National Heart, Lung, and Blood Institute
  

Notice of Changes to Funding Opportunities

• Notice to Change Eligibility in NOT-MD-22-001, "Notice of Special Interest (NOSI): Administrative Supplements to Support Addiction Science and Related Neuroscience Pilot Research Projects at NIMHD-Funded Research Centers in Minority Institutions (RCMI)"
  (NOT-MD-22-003)
  National Institute on Minority Health and Health Disparities
  

Notices of Intent to Publish

• Notice of Intent to Publish a Funding Opportunity Announcement for Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE) (R01 Clinical Trial Not Allowed)
  (NOT-CA-22-026)
  National Cancer Institute
  

• Notice of Intent to Publish a Funding Opportunity Announcement for Copy of Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE) (R21 Clinical Trial Not Allowed)
  (NOT-CA-22-027)
  National Cancer Institute
  

• Notice of Intent to Publish a Funding Opportunity Announcement for Cancer Control Research in Persistent Poverty Areas (U54 Clinical Trial Optional)
  (NOT-CA-22-030)
  National Cancer Institute
  

• Notice of Intent to Publish a Funding Opportunity Announcement for Bioengineering Partnership with Industry (BPI) (U01 Clinical Trial Optional)
  (NOT-EB-21-023)
  National Institute of Biomedical Imaging and Bioengineering
  

• Notice of Intent to Publish a Funding Opportunity Announcement for Biomedical-engineering Partnership with Industry (U01 Clinical Trial Not Allowed)
  (NOT-EB-21-024)
  National Institute of Biomedical Imaging and Bioengineering
  

• Notice of Intent to Publish a Funding Opportunity Announcement for Advancing Integrated Models (AIM) of Care to Improve Maternal Health Outcomes among Women Who Experience Persistent Disparities (R01 Clinical Trial Required)
  (NOT-NR-22-002)
  National Institute of Nursing Research
  National Institute on Minority Health and Health Disparities
  

• Notice of Intent to Publish a Funding Opportunity Announcement for Advancing Integrated Models (AIM) of Care to Improve Maternal Health Outcomes among Women Who Experience Persistent Disparities (R21 Clinical Trial Optional)
  (NOT-NR-22-003)
  National Institute of Nursing Research
  

• Notice of Intent to Publish a Funding Opportunity Announcement for HEAL Initiative: Human Pain-associated Genes & Cells Data Coordination and Integration Center (U24 Clinical Trial Not Allowed)
  (NOT-NS-22-063)
  National Institute of Neurological Disorders and Stroke
  

• Notice of Intent to Publish a Funding Opportunity Announcement for HEAL Initiative: Discovery and Functional Evaluation of Human Pain-associated Genes & Cells (U19 Clinical Trial Not Allowed)
  (NOT-NS-22-065)
  National Institute of Neurological Disorders and Stroke
  

Notices of Special Interest

• Notice of Special Interest: Health Disparities and Alzheimer's Disease
  (NOT-AG-21-033)
  National Institute on Aging
  Office of Research on Women's Health
  

• Notice of Special Interest (NOSI): Genetic Underpinnings of Endosomal Trafficking as a Pathological Hub in Alzheimer's Disease and Alzheimer's Disease-Related Dementias (AD/ADRD)
  (NOT-AG-21-034)
  National Institute on Aging
  

• Notice of Special Interest: Collaborative Studies on Alzheimer's Disease and Alzheimer's Disease-Related Dementias (AD/ADRD)
  (NOT-AG-21-035)
  National Institute on Aging
  

• Notice of Special Interest: Common Mechanisms and Interactions Among Neurodegenerative Diseases
  (NOT-AG-21-037)
  National Institute on Aging
  

• Notice of Special Interest: Understanding Alzheimer's Disease in the Context of the Aging Brain
  (NOT-AG-21-039)
  National Institute on Aging
  

• Notice of Special Interest: Promoting Research on COVID-19 and Rheumatic, Musculoskeletal and Skin Diseases
  (NOT-AR-22-012)
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  

• Notice of Special Interest (NOSI): Advancing Innovative Non-invasive Physiologic Monitoring To Improve Fetal Assessment
  (NOT-HD-21-053)
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  

• Notice of Special Interest (NOSI) in NINDS mission relevant Pain Research
  (NOT-NS-22-050)
  National Institute of Neurological Disorders and Stroke
  

• Notice of Special Interest (NOSI) in Migraine and Headache Research
  (NOT-NS-22-051)
  National Institute of Neurological Disorders and Stroke
  

Funding Opportunities

• Lipids in Brain Aging and Alzheimer's Disease (AD) and its Related Dementias (ADRD) (R01 Clinical Trial Not Allowed)
  (RFA-AG-23-009)
  National Institute on Aging
  Application Receipt Date(s): June 14, 2022
  
  

• HEAL Initiative: Planning Grants for Efficacy or Effectiveness Trials of Recovery Support Services for Individuals Treated with Medications for Opioid Use Disorder (R34 Clinical Trial Optional)
  (RFA-DA-22-034)
  National Institute on Drug Abuse
  National Center for Complementary and Integrative Health
  National Institute on Aging
  National Institute on Alcohol Abuse and Alcoholism
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  Application Receipt Date(s): March 10, 2022
  
  

• HEAL Initiative: Harm Reduction Policies, Practices, and Modes of Delivery for Persons with Substance Use Disorders: Coordination Center (R24 Clinical Trial Optional)
  (RFA-DA-22-042)
  National Institute on Drug Abuse
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  Application Receipt Date(s): March 10, 2022
  
  

• HEAL Initiative: Research Networks for the Study of Recovery Support Services for Persons Treated with Medications for Opioid Use Disorder (R24 Clinical Trial Optional)
  (RFA-DA-22-043)
  National Institute on Drug Abuse
  National Center for Complementary and Integrative Health
  National Institute on Aging
  National Institute on Alcohol Abuse and Alcoholism
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  Application Receipt Date(s): March 10, 2022
  
  

• HEAL Initiative: Harm Reduction Policies, Practices, and Modes of Delivery for Persons with Substance Use Disorders (R01 Clinical Trial Optional)
  (RFA-DA-22-046)
  National Institute on Drug Abuse
  National Center for Complementary and Integrative Health
  National Institute on Aging
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  Application Receipt Date(s): March 10, 2022
  
  

• HEAL Initiative: Understanding Polysubstance Use and Improving Service Delivery to Address Polysubstance Use (R01 Clinical Trial Optional)
  (RFA-DA-22-047)
  National Institute on Drug Abuse
  National Center for Complementary and Integrative Health
  National Institute on Aging
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  Application Receipt Date(s): March 10, 2022
  
  

• HEAL Initiative: Pilot and Feasibility Trials to Improve Prevention and Treatment Service Delivery for Polysubstance Use (R34 Clinical Trial Optional)
  (RFA-DA-22-048)
  National Institute on Drug Abuse
  National Center for Complementary and Integrative Health
  National Institute on Aging
  National Institute on Alcohol Abuse and Alcoholism
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  Application Receipt Date(s): March 10, 2022